QCG
RLAY icon

Quadrant Capital Group’s Relay Therapeutics RLAY Stock Holding History

Quadrant Capital Group’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$221K Hold
11,791
– – 0.01% 1176
2026
Q1 		$117K Hold
11,791
– – ﹤0.01% 1437
2025
Q4 		$99.8K Hold
11,791
– – ﹤0.01% 1488
2025
Q3 		$61.5K Hold
11,791
– – ﹤0.01% 1599
2025
Q2 		$40.8K Buy
11,791
+8,374
+245% +$24.9K ﹤0.01% 1328
2025
Q1 		$8.95K Buy
3,417
+2,972
+668% +$11.6K ﹤0.01% 2240
2024
Q4 		$1.83K Buy
445
+394
+773% +$2.14K ﹤0.01% 2505
2024
Q3 		$362 Sell
51
-1,045
-95% -$7.81K ﹤0.01% 2679
2024
Q2 		$7.15K Buy
+1,096
New +$7.49K ﹤0.01% 2207
2023
Q1 		– Sell
-72
Closed -$1.08K – 2777
2022
Q4 		$1.08K Buy
+72
New +$1.38K ﹤0.01% 2535

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Quadrant Capital Group's RLAY Position: Q2 2026 in Review

Quadrant Capital Group held its Relay Therapeutics (RLAY) position steady in Q2 2026 at 11,791 shares worth $221K. The position accounts for 0.01% of the portfolio, ranked #1176.

Quadrant Capital Group first reported a position in RLAY in Q4 2022 and has held it in 10 quarters since. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Quadrant Capital Group held 11,791 shares of Relay Therapeutics worth $221K as of Q2 2026.
  • Quadrant Capital Group left its Relay Therapeutics share count unchanged in Q2 2026.
  • Relay Therapeutics made up 0.01% of Quadrant Capital Group's portfolio in Q2 2026, its #1176 holding.
  • Quadrant Capital Group first reported a position in Relay Therapeutics in Q4 2022 and has held it in 10 quarters since.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.